Fannie Mae, Freddie Mac shares tumble after conservatorship comments
Investing.com - Intuitive Surgical (NASDAQ:ISRG), currently trading at $511 with a market capitalization of $183 billion, received a reiterated Buy rating and $670.00 price target from Stifel on Wednesday, following the company’s second-quarter performance and progress with its next-generation DV5 robotic system. According to InvestingPro data, the stock trades at a premium valuation with a P/E ratio of 74x.
The medical device maker reported 180 DV5 system placements in the second quarter of 2025, up from 147 in the first quarter, signaling the broad launch of the next-generation surgical robot has commenced successfully under new CEO Dave Rosa, who took the helm on July 1, 2025.
Intuitive Surgical expanded its international reach for the DV5 system, securing regulatory approvals in Japan in June and Europe in July, opening access to the company’s top overseas markets.
The company maintained healthy procedure growth at approximately 17% during the quarter, which Stifel identified as a key performance indicator for future system placements and overall outlook.
Operating margins reached 38.8% in the second quarter, the highest level since the third quarter of 2021, benefiting from positive capital sales mix and lower-than-expected expenses, according to Stifel’s analysis. For deeper insights into Intuitive Surgical’s valuation and growth prospects, including 13 additional key ProTips, check out the comprehensive Pro Research Report available on InvestingPro.
In other recent news, Intuitive Surgical has reported impressive second-quarter results, significantly surpassing analysts’ expectations. The company achieved earnings per share of $2.19, which is notably higher than the consensus estimate of $1.92, marking a 23% year-over-year growth. Revenue for the quarter reached $2.44 billion, reflecting a 21% increase from the previous year and exceeding the anticipated $2.35 billion. This strong performance led several analyst firms to adjust their price targets for the company. Raymond (NSE:RYMD) James reiterated its Outperform rating, maintaining a price target of $592. BTIG raised its price target to $571 while maintaining a Buy rating. Piper Sandler increased its target to $595, citing the company’s robust operating margin performance. Baird also raised its price target to $600, highlighting the company’s accelerating growth across all segments. These developments underscore the positive market sentiment surrounding Intuitive Surgical’s recent performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.